JP2017507131A5 - - Google Patents

Download PDF

Info

Publication number
JP2017507131A5
JP2017507131A5 JP2016550573A JP2016550573A JP2017507131A5 JP 2017507131 A5 JP2017507131 A5 JP 2017507131A5 JP 2016550573 A JP2016550573 A JP 2016550573A JP 2016550573 A JP2016550573 A JP 2016550573A JP 2017507131 A5 JP2017507131 A5 JP 2017507131A5
Authority
JP
Japan
Prior art keywords
antibody
seq
antibody agent
agent according
residues
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016550573A
Other languages
English (en)
Japanese (ja)
Other versions
JP6707455B2 (ja
JP2017507131A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/015510 external-priority patent/WO2015123362A1/en
Publication of JP2017507131A publication Critical patent/JP2017507131A/ja
Publication of JP2017507131A5 publication Critical patent/JP2017507131A5/ja
Application granted granted Critical
Publication of JP6707455B2 publication Critical patent/JP6707455B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016550573A 2014-02-11 2015-02-11 新規フルスペクトル抗デング抗体 Active JP6707455B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461938605P 2014-02-11 2014-02-11
US61/938,605 2014-02-11
PCT/US2015/015510 WO2015123362A1 (en) 2014-02-11 2015-02-11 Novel full spectrum anti-dengue antibody

Publications (3)

Publication Number Publication Date
JP2017507131A JP2017507131A (ja) 2017-03-16
JP2017507131A5 true JP2017507131A5 (enExample) 2018-03-22
JP6707455B2 JP6707455B2 (ja) 2020-06-10

Family

ID=53800606

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016550573A Active JP6707455B2 (ja) 2014-02-11 2015-02-11 新規フルスペクトル抗デング抗体

Country Status (12)

Country Link
US (3) US9902764B2 (enExample)
EP (1) EP3104888A4 (enExample)
JP (1) JP6707455B2 (enExample)
KR (1) KR20160119806A (enExample)
CN (1) CN106413749B (enExample)
AU (1) AU2015217149B2 (enExample)
BR (1) BR112016017764A2 (enExample)
CA (1) CA2938495A1 (enExample)
IL (1) IL246788A0 (enExample)
MX (1) MX375402B (enExample)
SG (2) SG10201807826XA (enExample)
WO (1) WO2015123362A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2687808T3 (es) 2007-09-26 2018-10-29 Chugai Seiyaku Kabushiki Kaisha Región constante de anticuerpo modificado
TWI544077B (zh) 2009-03-19 2016-08-01 中外製藥股份有限公司 Antibody constant region change body
AU2013299986B2 (en) 2012-08-07 2018-05-17 Massachusetts Institute Of Technology Anti-dengue virus antibodies and uses thereof
JP6764348B2 (ja) 2014-02-11 2020-09-30 ビステラ, インコーポレイテッド デングウイルスに対する抗体分子およびその使用
AU2015217149B2 (en) 2014-02-11 2020-09-10 Massachusetts Institute Of Technology Novel full spectrum anti-dengue antibody
CN114773469B (zh) 2015-02-05 2025-12-19 中外制药株式会社 包含离子浓度依赖性的抗原结合结构域的抗体,fc区变体,il-8-结合抗体及其应用
EP3433274A1 (en) 2016-03-25 2019-01-30 Visterra, Inc. Formulation of antibody molecules to dengue virus
CN116271014A (zh) 2016-08-05 2023-06-23 中外制药株式会社 用于预防或治疗il-8相关疾病的组合物
SG10201607778XA (en) 2016-09-16 2018-04-27 Chugai Pharmaceutical Co Ltd Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
JP2022008719A (ja) * 2016-11-23 2022-01-14 セルヴァス エーアイ インコーポレイテッド 疾患発症予測方法及び装置
BR112019011900A2 (pt) 2016-12-23 2019-11-26 Serum Institute Of India Private Limited métodos melhorados para aumentar a produtividade de anticorpos na cultura de células de mamíferos e minimizar a agregação durante os processos downs-tream, processos de formulação, e formulações de anticorpos estáveis obtidas dos mesmos
TWI827585B (zh) 2018-03-15 2024-01-01 日商中外製藥股份有限公司 對茲卡病毒具有交叉反應性的抗登革病毒抗體及其使用方法

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4957939A (en) 1981-07-24 1990-09-18 Schering Aktiengesellschaft Sterile pharmaceutical compositions of gadolinium chelates useful enhancing NMR imaging
US4472509A (en) 1982-06-07 1984-09-18 Gansow Otto A Metal chelate conjugated monoclonal antibodies
US4938948A (en) 1985-10-07 1990-07-03 Cetus Corporation Method for imaging breast tumors using labeled monoclonal anti-human breast cancer antibodies
US5750172A (en) 1987-06-23 1998-05-12 Pharming B.V. Transgenic non human mammal milk
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
JPH049249A (ja) 1990-04-27 1992-01-14 Kusuda:Kk 塗型剤吹き付け機
AU693436B2 (en) 1993-03-09 1998-07-02 Genzyme Corporation Isolation of components of interest from milk
US5500161A (en) 1993-09-21 1996-03-19 Massachusetts Institute Of Technology And Virus Research Institute Method for making hydrophobic polymeric microparticles
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
JPH07299655A (ja) 1994-04-30 1995-11-14 Aisin Seiki Co Ltd 内スプライン歯面仕上機
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
WO2003029462A1 (en) 2001-09-27 2003-04-10 Pieris Proteolab Ag Muteins of human neutrophil gelatinase-associated lipocalin and related proteins
US7118915B2 (en) 2001-09-27 2006-10-10 Pieris Proteolab Ag Muteins of apolipoprotein D
AU2003210060B2 (en) 2002-03-22 2010-02-25 Aprogen, Inc. Humanized antibody and process for preparing same
US7232888B2 (en) 2002-07-01 2007-06-19 Massachusetts Institute Of Technology Antibodies against tumor surface antigens
CA2503871C (en) 2002-11-01 2012-12-11 Glaxosmithkline Biologicals S.A. An immunogenic composition for generating an immune response against polio virus
US7622113B2 (en) * 2003-12-08 2009-11-24 The United States Of America As Represented By The Department Of Health And Human Services Monoclonal antibodies that bind or neutralize dengue virus
US7892827B2 (en) 2004-11-26 2011-02-22 Pieris Ag Compound with affinity for the cytotoxic T lymphocyte-associated antigen (CTLA-4)
WO2007021672A2 (en) 2005-08-10 2007-02-22 Acambis Inc. Vaccination against dengue virus infection
CU23586A1 (es) 2005-11-22 2010-10-30 Ct Ingenieria Genetica Biotech Métodos y proteínas para el tratamiento profiláctico y/o terapéutico de los cuatro serotipos del virus de dengue y otros flavivirus
CU23632A1 (es) 2006-04-28 2011-02-24 Ct Ingenieria Genetica Biotech Métodos para la identificación de candidatos terapéuticos contra enfermedades causadas por flavivirus y moléculas antivirales.
JP6074574B2 (ja) 2008-02-05 2017-02-08 バイシクル セラピューティクス リミテッド 方法及び組成物
CA2738644A1 (en) * 2008-10-05 2010-05-08 The Board Of Trustees Of The Leland Stanford Junior University Hepatitis c antibodies and uses thereof
WO2010043977A2 (en) 2008-10-13 2010-04-22 Institute For Research In Biomedicine Dengue virus neutralizing antibodies and uses thereof
EP2374001A4 (en) 2008-12-05 2013-03-13 Lpath Inc ANTIBODY DESIGN USING ANTI-LIPID ANTIBODY CRYSTAL STRUCTURES
WO2010093335A1 (en) 2009-02-10 2010-08-19 Nanyang Technological University Antibodies for diagnosis and treatment of flaviviral infections
EP2353609A1 (en) 2010-02-04 2011-08-10 Sanofi Pasteur Immunization compositions and methods
US8637035B2 (en) * 2010-07-16 2014-01-28 Academia Sinica Anti-dengue virus antibodies
US20140349321A1 (en) 2011-12-16 2014-11-27 Agency For Science, Technology And Research Binding molecules against dengue virus and uses thereof
US9556254B2 (en) * 2012-05-14 2017-01-31 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Cross-reactive antibodies against dengue virus and uses thereof
AU2013299986B2 (en) 2012-08-07 2018-05-17 Massachusetts Institute Of Technology Anti-dengue virus antibodies and uses thereof
AU2015217149B2 (en) 2014-02-11 2020-09-10 Massachusetts Institute Of Technology Novel full spectrum anti-dengue antibody
JP6764348B2 (ja) 2014-02-11 2020-09-30 ビステラ, インコーポレイテッド デングウイルスに対する抗体分子およびその使用

Similar Documents

Publication Publication Date Title
JP2020522261A5 (enExample)
JP2016529882A5 (enExample)
RU2015136078A (ru) Антитело против с5 и способ предупреждения и лечения обусловленных комплементом заболеваний
JP2015503909A5 (enExample)
JP2015525795A5 (enExample)
JP2011509245A5 (enExample)
IL261666B1 (en) Binding proteins and methods of use thereof
JP2018502060A5 (enExample)
JP2018508188A5 (enExample)
JP2013502913A5 (enExample)
JP2010536384A5 (enExample)
JP2017505121A5 (enExample)
JP2014534806A5 (enExample)
JP2023549067A5 (enExample)
JP2021500916A5 (enExample)
RU2018129874A (ru) Антитела против фактора свертывания xi
RU2016100892A (ru) Антитела против tweakr и их применение
US12173081B2 (en) CD19/CD38 multispecific antibodies
JP2017537082A5 (enExample)
JP2005528914A5 (enExample)
JP2015514068A5 (enExample)
JP2013508292A5 (enExample)
JP2016501877A5 (enExample)
JP2022517216A5 (enExample)
CN110461874B (zh) 抗gitr抗体、其抗原结合片段及其医药用途